CA3186033A1 - Methods for encapsulating polynucleotides into reduced sizes of lipid nanoparticles and novel formulation thereof - Google Patents
Methods for encapsulating polynucleotides into reduced sizes of lipid nanoparticles and novel formulation thereof Download PDFInfo
- Publication number
- CA3186033A1 CA3186033A1 CA3186033A CA3186033A CA3186033A1 CA 3186033 A1 CA3186033 A1 CA 3186033A1 CA 3186033 A CA3186033 A CA 3186033A CA 3186033 A CA3186033 A CA 3186033A CA 3186033 A1 CA3186033 A1 CA 3186033A1
- Authority
- CA
- Canada
- Prior art keywords
- lipid
- pharmaceutical composition
- cedna
- alkyl
- lnp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Dispersion Chemistry (AREA)
- Optics & Photonics (AREA)
- Nanotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063053274P | 2020-07-17 | 2020-07-17 | |
| US63/053,274 | 2020-07-17 | ||
| US202163194620P | 2021-05-28 | 2021-05-28 | |
| US63/194,620 | 2021-05-28 | ||
| PCT/US2021/042033 WO2022016089A2 (en) | 2020-07-17 | 2021-07-16 | Methods for encapsulating polynucleotides into reduced sizes of lipid nanoparticles and novel formulation thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3186033A1 true CA3186033A1 (en) | 2022-01-20 |
Family
ID=79555025
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3186033A Pending CA3186033A1 (en) | 2020-07-17 | 2021-07-16 | Methods for encapsulating polynucleotides into reduced sizes of lipid nanoparticles and novel formulation thereof |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230320993A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4181948A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2023534043A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230052895A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116437964A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021307952A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3186033A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL299896A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023000806A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022016089A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11752213B2 (en) | 2015-12-21 | 2023-09-12 | Duke University | Surfaces having reduced non-specific binding and antigenicity |
| KR20190064600A (ko) | 2016-09-23 | 2019-06-10 | 듀크 유니버시티 | Lcst 거동을 갖는 비구조화된 비-반복적 폴리펩티드 |
| EP3658168A4 (en) | 2017-06-30 | 2021-07-14 | Duke University | ORDER AND DISORDER AS A DESIGN PRINCIPLE FOR STIMULI-RESPONDING BIOPOLYMER NETWORKS |
| WO2019147954A1 (en) | 2018-01-26 | 2019-08-01 | Duke University | Albumin binding peptide-drug (aibiped) conjugates and methods of making and using same |
| WO2019213150A1 (en) | 2018-04-30 | 2019-11-07 | Duke University | Stimuli-responsive peg-like polymer-based drug delivery platform |
| WO2020051541A1 (en) | 2018-09-07 | 2020-03-12 | Duke University | Nanoparticulate drug delivery systems |
| DK3864163T3 (da) | 2018-10-09 | 2024-05-06 | Univ British Columbia | Sammensætninger og systemer omfattende transfektionskompetente vesikler fri for organiske opløsningsmidler og rengøringsmidler og fremgangsmåder forbundet dermed |
| US11512314B2 (en) | 2019-07-12 | 2022-11-29 | Duke University | Amphiphilic polynucleotides |
| US12534435B2 (en) * | 2020-03-27 | 2026-01-27 | Generation Bio Co. | Lipids and nanoparticle compositions thereof |
| MX2023012369A (es) | 2021-04-20 | 2024-01-08 | Generation Bio Co | Lípidos catiónicos y composiciones de estos. |
| CA3215963A1 (en) * | 2021-05-28 | 2022-12-01 | Yaoxin LIN | Lipid compound and use thereof in delivery of nucleic acid |
| CN117642380A (zh) * | 2021-06-14 | 2024-03-01 | 世代生物公司 | 阳离子脂质及其组合物 |
| US20250281596A1 (en) * | 2021-09-28 | 2025-09-11 | Seqirus Inc. | Ionizable cationic compound |
| EP4422605A4 (en) * | 2021-10-25 | 2025-06-18 | Duke University | Poegma-based lipid nanoparticles |
| US20250213478A1 (en) * | 2022-03-28 | 2025-07-03 | Nof Corporation | Cationic lipid having disulfide bond, lipid membrane structure including same, nucleic acid introduction agent and pharmaceutical composition containing any one of same, method for introducing nucleic acid into cell or target cell, and method for producing cellular pharmaceutical |
| CN114685784B (zh) * | 2022-04-26 | 2023-09-15 | 北京清科胜因生物科技有限公司 | 一种用于核酸递送的聚(2-噁唑啉)脂质与脂质纳米颗粒及应用 |
| WO2023239756A1 (en) * | 2022-06-07 | 2023-12-14 | Generation Bio Co. | Lipid nanoparticle compositions and uses thereof |
| CN115105584B (zh) * | 2022-06-28 | 2023-03-31 | 长春生物制品研究所有限责任公司 | 一种卡式瓶多剂量笔式注射组合包装的干扰素注射液 |
| WO2024037577A1 (en) * | 2022-08-18 | 2024-02-22 | Suzhou Abogen Biosciences Co., Ltd. | Composition of lipid nanoparticles |
| CN120112275A (zh) * | 2022-08-25 | 2025-06-06 | 俄亥俄州创新基金会 | 用于递送包括核酸的活性剂的组合物和方法 |
| US20240150306A1 (en) * | 2022-09-27 | 2024-05-09 | Reinvigoron Theratech, Inc. | Compounds with cleavable disulfide moieties |
| JP2025535566A (ja) * | 2022-11-08 | 2025-10-24 | サムヤン ホールディングス コーポレイション | カチオン性脂質及びその製造方法 |
| EP4626402A1 (en) | 2022-12-01 | 2025-10-08 | Generation Bio Co. | Lipid nanoparticles comprising nucleic acids and lipid-anchored polymers |
| EP4704855A1 (en) * | 2023-04-26 | 2026-03-11 | Saliogen Therapeutics, Inc. | Lipid nanoparticle (lnp) formulations |
| EP4719352A1 (en) | 2023-05-31 | 2026-04-08 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| WO2025043146A2 (en) * | 2023-08-24 | 2025-02-27 | Molecular Axiom Inc. | Lipid nanoparticle compositions and methods of using same |
| WO2025064850A1 (en) | 2023-09-22 | 2025-03-27 | BioNTech SE | Rna constructs with n-terminal degrons to enhance an immune response |
| FR3155424A1 (fr) | 2023-11-15 | 2025-05-23 | BioNTech SE | Compositions immunogènes contre le sars-cov-2 |
| WO2025106754A1 (en) | 2023-11-15 | 2025-05-22 | BioNTech SE | Coronavirus vaccine |
| WO2025149492A1 (en) | 2024-01-08 | 2025-07-17 | BioNTech SE | Rna encoding an immune inhibitory il-1 family member |
| WO2025166238A1 (en) * | 2024-01-31 | 2025-08-07 | Orna Therapeutics, Inc. | Fast-shedding polyethylene glycol lipids |
| WO2025178465A1 (ko) * | 2024-02-19 | 2025-08-28 | 주식회사 메디치바이오 | 신규한 이온화 지질 및 이를 이용한 지질 나노입자 조성물 |
| WO2025230906A1 (en) * | 2024-04-29 | 2025-11-06 | Saliogen Therapeutics, Inc. | Lipid nanoparticle (lnp) formulations |
| WO2025237830A1 (en) * | 2024-05-15 | 2025-11-20 | Evonik Operations Gmbh | Polyoxyalkylene-1,2-di(alkyloxy)propanoxy-carbonylaminopropyl compounds, wherein the polyoxyalkylene is a poly(ethylene oxide) having c1 to c3-alkyloxymethyl side chains |
| WO2025255027A1 (en) * | 2024-06-03 | 2025-12-11 | Flagship Labs 114, Inc. | Lipid nanoparticles for topical delivery |
| WO2026047603A1 (en) | 2024-08-28 | 2026-03-05 | BioNTech SE | Sars-cov-2 immunogenic compositions |
| WO2026057626A1 (en) | 2024-09-11 | 2026-03-19 | BioNTech SE | Peptidoglycan hydrolases having multiple enzymatically active domains |
| WO2026057625A1 (en) | 2024-09-11 | 2026-03-19 | BioNTech SE | Peptidoglycan hydrolases having a chap domain with engineered active site |
| WO2026068864A1 (en) | 2024-09-30 | 2026-04-02 | BioNTech SE | Engineered ch1 and cl domains for the prevention of chain mispairing |
| WO2026082899A2 (en) | 2024-10-16 | 2026-04-23 | BioNTech SE | Rna for preventing or treating tuberculosis |
| WO2026090590A1 (en) * | 2024-10-25 | 2026-04-30 | Remedium Bio, Inc. | Nanoparticle formulations for the delivery of dna to adipose tissue |
| WO2026119817A1 (en) | 2024-12-02 | 2026-06-11 | BioNTech SE | Agents and methods for targeted delivery of immune effector cells |
| WO2026125598A1 (en) | 2024-12-13 | 2026-06-18 | BioNTech SE | Measuring nucleic acid integrity |
| WO2026125590A1 (en) | 2024-12-13 | 2026-06-18 | BioNTech SE | Measuring nucleic acid integrity |
| WO2026148356A1 (en) | 2025-01-06 | 2026-07-09 | BioNTech SE | Coronavirus and influenza immunogenic combinations |
| WO2026150132A1 (en) | 2025-01-12 | 2026-07-16 | BioNTech SE | Combination therapy comprising an rna cancer vaccine and a multispecific binding agent targeting pd-1/pd-l1 and vegf/vegfr for cancer treatment |
| WO2026162682A1 (en) | 2025-01-29 | 2026-08-06 | BioNTech SE | Compositions for delivery of plasmodium rh5 antigens and related methods |
| WO2026162552A1 (en) | 2025-01-31 | 2026-08-06 | BioNTech SE | Agents and methods for targeted delivery to cells |
| CN121421963B (zh) * | 2026-01-04 | 2026-05-05 | 广州隽沐生物科技股份有限公司 | 一种用于难溶性活性经皮黏膜给药的装配材料及制备方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008103276A2 (en) * | 2007-02-16 | 2008-08-28 | Merck & Co., Inc. | Compositions and methods for potentiated activity of biologicaly active molecules |
| WO2013073480A1 (ja) * | 2011-11-18 | 2013-05-23 | 日油株式会社 | 細胞内動態を改善したカチオン性脂質 |
| HK1206644A1 (en) * | 2012-03-29 | 2016-01-15 | Shire Human Genetic Therapies, Inc. | Lipid-derived neutral nanoparticles |
| HRP20220156T1 (hr) * | 2015-09-17 | 2022-04-15 | Modernatx, Inc. | Spojevi i pripravci za unutarstaničnu isporuku terapeutskih sredstava |
| US11395798B2 (en) * | 2015-10-08 | 2022-07-26 | Nof Corporation | O/W type emulsion |
| US11410746B2 (en) * | 2016-04-27 | 2022-08-09 | Massachusetts Institute Of Technology | Stable nanoscale nucleic acid assemblies and methods thereof |
| EP3538067A1 (en) * | 2016-11-08 | 2019-09-18 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
| EP3679148A4 (en) * | 2017-09-08 | 2021-06-09 | Generation Bio Co. | LIPID NANOPARTICLE FORMULATIONS FROM NONVIRAL, CAPSID-FREE DNA VECTORS |
| CA3094057C (en) * | 2018-03-27 | 2025-04-08 | Nof Corporation | CATIONIC LIPID WITH IMPROVED INTRACELLULAR DYNAMICS |
| CN114929205B (zh) * | 2019-09-06 | 2024-09-03 | 世代生物公司 | 包括末端封闭式dna和可切割脂质的脂质纳米颗粒组合物及其使用方法 |
| AU2020385378A1 (en) * | 2019-11-22 | 2022-04-07 | Generation Bio Co. | Ionizable lipids and nanoparticle compositions thereof |
| US12534435B2 (en) * | 2020-03-27 | 2026-01-27 | Generation Bio Co. | Lipids and nanoparticle compositions thereof |
| CN115968280A (zh) * | 2020-05-18 | 2023-04-14 | 世代生物公司 | 新型脂质及其纳米颗粒组合物 |
-
2021
- 2021-07-16 AU AU2021307952A patent/AU2021307952A1/en active Pending
- 2021-07-16 JP JP2023502945A patent/JP2023534043A/ja active Pending
- 2021-07-16 US US18/015,575 patent/US20230320993A1/en not_active Abandoned
- 2021-07-16 EP EP21842533.8A patent/EP4181948A4/en active Pending
- 2021-07-16 IL IL299896A patent/IL299896A/en unknown
- 2021-07-16 WO PCT/US2021/042033 patent/WO2022016089A2/en not_active Ceased
- 2021-07-16 CA CA3186033A patent/CA3186033A1/en active Pending
- 2021-07-16 CN CN202180063144.XA patent/CN116437964A/zh active Pending
- 2021-07-16 KR KR1020237005643A patent/KR20230052895A/ko active Pending
- 2021-07-16 MX MX2023000806A patent/MX2023000806A/es unknown
-
2026
- 2026-02-05 JP JP2026017935A patent/JP2026074198A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4181948A4 (en) | 2024-12-04 |
| US20230320993A1 (en) | 2023-10-12 |
| AU2021307952A1 (en) | 2023-03-02 |
| WO2022016089A3 (en) | 2022-03-03 |
| MX2023000806A (es) | 2023-04-11 |
| WO2022016089A2 (en) | 2022-01-20 |
| KR20230052895A (ko) | 2023-04-20 |
| IL299896A (en) | 2023-03-01 |
| EP4181948A2 (en) | 2023-05-24 |
| JP2023534043A (ja) | 2023-08-07 |
| CN116437964A (zh) | 2023-07-14 |
| JP2026074198A (ja) | 2026-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230320993A1 (en) | Methods for encapsulating polynucleotides into reduced sizes of lipid nanoparticles and novel formulation thereof | |
| US12252470B2 (en) | Lipids and nanoparticle compositions thereof | |
| US12263228B2 (en) | Lipids and compositions thereof | |
| WO2021102411A1 (en) | Ionizable lipids and nanoparticle compositions thereof | |
| WO2022261101A1 (en) | Apoe and apob modified lipid nanoparticle compositions and uses thereof | |
| WO2022266032A1 (en) | Cationic lipids and compositions thereof | |
| US20230181764A1 (en) | Novel lipids and nanoparticle compositions thereof | |
| CN117545469A (zh) | 阳离子脂质及其组合物 | |
| CA3154774C (en) | Ionizable lipids and nanoparticle compositions thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250711 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250711 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20250716 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20250716 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250716 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250717 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250923 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250923 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250923 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250923 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250923 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260710 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260710 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20260721 |